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Abstract
Background
Epithelial cells in malignant conditions release DNA into the extracellular compartment. Cell
free DNA of tumor origin may act as a ligand of DNA sensing mechanisms and mediate
changes in epithelial-stromal interactions.
Aims
To evaluate and compare the potential autocrine and paracrine regulatory effect of normal
and malignant epithelial cell-related DNA on TLR9 and STINGmediated pathways in HT-29
human colorectal adenocarcinoma cells and normal fibroblasts.
Materials and Methods
DNA isolated from normal and tumorous colonic epithelia of fresh frozen surgically removed
tissue samples was used for 24 and 6 hour treatment of HT-29 colon carcinoma and HDF-α
fibroblast cells. Whole genome mRNA expression analysis and qRT-PCR was performed
for the elements/members of TLR9 signaling pathway. Immunocytochemistry was per-
formed for epithelial markers (i.e. CK20 and E-cadherin), DNA methyltransferase 3a
(DNMT3a) and NFκB (for treated HDFα cells).
Results
Administration of tumor derived DNA on HT29 cells resulted in significant (p<0.05) mRNA
level alteration in 118 genes (logFc1, p0.05), including overexpression of metallothio-
nein genes (i.e.MT1H,MT1X,MT1P2,MT2A), metastasis-associated genes (i.e.
TACSTD2,MACC1,MALAT1), tumor biomarker (CEACAM5), metabolic genes (i.e.
INSIG1, LIPG), messenger molecule genes (i.e. DAPP, CREB3L2). Increased protein levels
of CK20, E-cadherin, and DNMT3a was observed after tumor DNA treatment in HT-29
cells. Healthy DNA treatment affected mRNA expression of 613 genes (logFc1, p0.05),
including increased expression of key adaptor molecules of TLR9 pathway (e.g.MYD88,
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gene.
Conclusions
DNA from tumorous colon epithelium, but not from the normal epithelial cells acts as a pro-
metastatic factor to HT-29 cells through the overexpression of pro-metastatic genes through
TLR9/MYD88 independent pathway. In contrast, DNA derived from healthy colonic epithe-
lium induced TLR9 and STING signaling pathway in normal fibroblasts.
Introduction
Altered epithelial-stromal interactions are fundamental in cancer formation. Among the well-
known regulatory ligands (e.g. growth factors, cytokines, chemokines, sex hormones) tumor
tissue-derived DNA is also involved in this communication via cellular receptors sensing DNA
[1] According to several studies [2–4] the DNA fragments of tumor origin (i.e. 21 to 500 bases
short sequences of human origin) play a role in the formation of a tumor supportive microen-
vironment (i.e. promote tumor invasion and evasion of immune surveillance) [5–8] The cell
free DNA originates from necrotic/apoptotic tumor cells, and can be actively released by living
cells to the intercellular compartment [9–12]. This tumor tissue originated DNA is detectable
in the plasma and serum and could serve a useful biomarker for cancer detection [11]. It con-
tains a number of cancer specific entities, including oncogenes, tumor suppressor genes, aber-
rant microsatellites, aberrant DNA methylation genes, and rearranged chromosomal DNA
[12]. Recent studies confirmed the uptake and the retention of oncogenes stimulating cell pro-
liferation in non-malignant cells after integration (oncometastasis) into the recipients cell´s
genome [13].
To the extent they are understood, the DNA sensing mechanisms in the target cells com-
prise two primary adaptor pathways, i.e. toll-like receptor (TLR9) and the stimulator of inter-
feron genes (STING) pathways.[14] Cytoplasmic TLR9 recognizes endogenous ligands, such as
danger-associated molecular patterns (DAMPs) like unmethylated DNA sequences [7, 8, 15]
The total amount of unmethylated DNA increases in parallel with global DNA hypomethyla-
tion in tumor tissue compared to the normal tissue [16]. The increased expression of TLR9 was
detected in several tumor types.[1, 17–20] Increased TLR9 expression in carcinoma cells was
associated with higher metastatic potential, while higher TLR9 expression by fibroblast-like
cells was associated with a low probability of metastasis [21]
The STING signaling pathway is an adaptor for DNA via binding of cyclic dinucleotides
generated by the enzyme cyclic GMP-AMP (cGAMP) synthase (cGAS).[22–24]
Strong synergism has been observed among cooperating STING and TLR9 signaling. These
two signaling pathways are differentially regulated by crucial adaptor molecules (IRF3/7,
STING, and MyD88) [25]. Furthermore Deng et al. (2014) and Woo et al. (2014) provided evi-
dence suggesting dendritic cells detect DNA from tumor cells via the STING-mediated, cyto-
solic DNA sensing pathway. [22, 26, 27]
Based on our previous results, HT-29 human colon adenocarcinoma cells reflected altered
DNAmethylation level (via elevated DNMT3a methyltranferase activity) and CK20 epithelial
marker expression after re—administration of self DNA.[28] In the present study we analyzed
the autocrine and paracrine effects of DNA from tumor and healthy tissue on HT-29 cancer
cells and fibroblasts by whole genomic mRNA expression analysis, and qRT PCR for validation
Tumor DNA Effect on Cancer Cells and Healthy Fibroblasts
PLOS ONE | DOI:10.1371/journal.pone.0131699 July 2, 2015 2 / 16
of genes from TLR9 pathway. Furthermore immunocytochemical analysis was performed for
selected differentiation markers, cell- adhesion molecules, and methyltransferases, for verifica-
tion at the protein level following treatment with DNA from healthy and tumor tissues.
Materials and Methods
HT-29 cell culture
HT-29 human colon adenocarcinoma cells were purchased from LGC STANDARDS (cat. No.
ATCC HTB-38) and cultured in a specific pathogen-free cell culture laboratory at 37°C in 5%
CO2. HT-29 cells were maintained in McCoy's 5a MediumModified (Cat No. M8403-500 mL
Sigma-Aldrich, St Louis, USA) supplemented with 10% (vol/vol) fetal bovine serum (FBS; Stan-
dard Quality; PAA Laboratories GmbH, Pasching, Austria), 160 μg/ml gentamycin (Sandoz,
Sandoz GmbH, Austria), and 125 μg/ml amphotericin B (Sigma-Aldrich, St Louis, USA).
HDFα cell culture
HDFα cells were purchased from Life technologies (cat. No. C0135C) and cultured in a specific
pathogen-free cell culture laboratory at 37°C in 5% CO2. HDFα cells were maintained in
Medium 106 (Life Technologies Corporation, Carlsbad, USA) supplemented with LSGS (Life
Technologies Corporation, Carlsbad, USA) and amphotericin B (Sigma). 160 μg/ml gentamy-
cin (Sandoz, Sandoz GmbH, Austria).
DNA isolation
Genomic DNA was isolated from macroscopically normal areas near colorectal cancers (CRC)
and from the tumorous tissue areas of surgically removed macrodissected fresh frozen CRC
samples (stage II, moderately differentiated tumors from sigmoid colon and rectum (25–50 mg
tissue) by High Pure PCR template preparation kit (Roche GmbH, Germany). These CRC
patients were all confirmed by definitive histological diagnosis and received no preoperative
chemotherapy or radiotherapy. The isolated, protein-free DNA was treated with 20 μl RNase
A/T1 Mix at 37°C for 1 hour (Thermo Scientific, Germany). The concentration of isolated and
purified DNA was determined by Nanodrop-1000 spectrophotometer (Thermo Scientific,
Germany).
Ethics statement
The study was conducted according to the declaration of Helsinki and approved by Semmel-
weis University Ethics Committee and the governmental Regional and Institutional Committee
of Science and Research Ethics (TUKEB), Nr: 23970-2/2011). Written informed consent was
obtained from all patients included in the study.
DNA treatment of HT-29 and HDFα cells
HT-29 and HDFα cells were seeded (at a density of 0.5x106 and 0.1x106) into 6 well Corning
CellBIND cell culture multiwell plates in RPMI 1640 supplemented with gentamycin, ampho-
tericin B and FBS. When monolayers reached 80–90% of confluency, 15 μg of normal or tumor
DNA (dissolved in 200 μl sterile phosphate buffered saline (PBS) were added to the wells. The
negative control comprised appropriate volumes of PBS. Cells were incubated at 37°C in a 5%
CO2 atmosphere and 95% humidity.
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Isolation of total RNA for Affymetrix HGU133 Plus 2.0 microarray and
qRT-PCR gene expression analyses
After 24 hours, cells were washed two times in 5 ml sterile PBS. After the second wash, cells
were resuspended in 5 ml PBS. 2.5 ml of cell suspension was used for total RNA isolation. Total
RNA from the isolated HT-29 cells was extracted with the RNeasy Mini kit (Qiagen, USA)
according to the instructions of the manufacturer. The isolated RNA was stored at -80°C.
mRNA expression microarray analysis
The quantity and quality of the isolated RNA were tested by measuring absorbance and by cap-
illary gelelectrophoresis using the 2100 Bioanalyzer and RNA 6000 Pico Kit (Agilent Inc, Santa
Clara, US). Biotinylated cRNA probes were synthesized from 4.82±0.60 μg total RNA and frag-
mented using the One-Cycle Target Labeling and Control Kit according to the Affymetrix
description. Ten μg of each fragmented cRNA sample were hybridized into HGU133 Plus2.0
array (Affymetrix) at 45°C for 16 hours. Microarrays were washed and stained using Fluidics
Station 450 (Affymetrix) and an antibody amplification staining method according to the man-
ufacturer's instructions. The fluorescent signals were detected by a GeneChip Scanner 3000
(Affymetrix).
Statistical evaluation of mRNA expression profiles
Pre-processing and quality control analyses were performed according to the suggestions of
The Tumour Analysis Best Practices Working Group (Tumor Analysis Best Practices Working
Group, 2004). Scanned images were inspected for artifacts; the percentage of present calls
(>25%) and degree of RNA degradation were evaluated. On the basis of evaluation criteria, all
measurements fulfilled the minimal quality requirements. In the case of HT29 and HDFα cell
experiments, the similarity of the 2–2 biological replicates was stated using the Euclidean dis-
tance method. Affymetrix expression arrays were pre-processed by gcRMA with quantile nor-
malization and median polish summarization.
Further analyses to identify differentially expressed features was performed with signifi-
cance analysis of microarrays (SAM). The nearest shrunken centroid method (prediction anal-
ysis of microarrays = PAM) was applied for sample classification from gene expression data.
Prediction analysis of microarrays uses soft thresholding to produce a shrunken centroid,
which allows the selection of characteristic genes with high predictive potential (Tibshirani
et al, 2002). Pre-processing, data mining and statistical steps were performed using Bioconduc-
tor libraries in the R-environment. Annotation and functional classification of discriminatory
genes were performed using the Affymetrix NetAffx system.
Reverse transcription and quantitative real time polymerase chain
reaction
After quantitative (Nanodrop) and qualitative analysis (BioAnalyzer RNA 6000 Pico Kit chip
kit RNA program; RIN>8 in all cases), reverse transcription was performed by using 1 μg of
total RNA (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, USA).
Quantitative real-time (qRT) PCR was performed using Probes Master and SYBR green
(Roche GmbH, Germany). Gene expression levels for each individual sample were normalized
to GAPDH expression. Mean relative gene expression was determined and differences were
calculated using the 2-ΔC(t) method. Oligonucleotide primers of TLR 9 (MYD88-dependent)
signaling pathway are listed in Table 1.
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Cell viability assays
0.1x106 HT-29 cells were seeded at a density of 0.1x106 into Corning CellBIND cell culture
multiwell plates in RPMI 1640, supplemented with gentamycin and FCS. After 24 hours, the
medium was changed; and, 15 μg of tumor and normal DNA [dissolved in 200 μl sterile phos-
phate buffered saline (PBS)] was added to the wells. The negative control is comprised of an
appropriate volume of PBS. Cells were incubated at 37°C in a 5% CO2 atmosphere and 95%
humidity for 72h.
After 72 hour treatment, the cells were harvested, washed twice in 0.5 ml sterile PBS, re-sus-
pended in 1.0 ml of ice cold 70% ethanol and stored at -20°C. Measurement was performed in
triplicates for each treatment group.
Samples were centrifuged for 3 min at 1300 rpm. Then, the cells were re-suspended in
300 μ1 of extraction buffer; and, 3 μl of RNAse (RNase A/T1 Mix, Thermo Fisher Scientific
Baltics UAB, Vilnius, Lithuania) was added. After 15 min incubation at room temperature, 3 μl
of propidium jodide (Sigma-Aldrich, St. Louis, USA; Cat. No. 81845) was added. The FACS
measurement was performed on BD FACScalibur (New Jersey, USA).
Trypan blue exclusion tests were performed to assess the cell viability following exposure to
tumor and normal cell free DNA. The HT-29 cell´s viability was then quantified by counting
the number of living and dead cells using a hemocytometer at the time point 72h post tumor
and normal DNA administration.
Table 1. List of the oligonucleotide primers of TLR9 (MYD88-dependent) signaling pathway.
Gene Symbol Gene title Sequence of selected primers
hTLR9_F human toll-like receptor 9 (fwd) CCTCCTGCTCAAGCTACACC
hTLR9_R human toll-like receptor 9 (reverse) CTTGTCCTTTTCTGCCCTTG
hMYD88_aF human MYD88 (forward) GAAGAAAGAGTTCCCCAGCA
hMYD88_aR human MYD88 (reverse) GTGCAGGGGTTGGTGTAGTC
hMYD88_bF human MYD88 (forward) CTCCTCCACATCCTCCCTTC
hMYD88_bR human MYD88 (reverse) CGCACGTTCAAGAACAGAGA
hIRAK2_F human interleukin associated kinase (forward) CTTGGAGTGGGCTTTCTGAG
hIRAK2_R human interleukin associated kinase (reverse) AGGCTGGAATTGTCAACGTC
hIRAK4_F human interleukin associated kinase(forward) GCTGCCTCAATGTTGGACTAA
hIRAK4_R human interleukin associated kinase(reverse) TTCCATCCTTCTTGAGGATCA
hTRAF6_F human tumor necrosis factor receptor associated factor 6 (forward) CTTTGGCAAATGTCATCTGTG
hTRAF6_R human tumor necrosis factor receptor associated factor 6 (reverse) CTGAATGTGCATGGAATTGG
hNFκB1_F human nuclear factor κB (forward) TATGTGGGACCAGCAAAGGT
hNFκB1_R human nuclear factor κB (reverse) GCAGATCCCATCCTCACAGT
hIL8_F human interleukin 8 (forward) GTGCAGTTTTGCCAAGGAGT
hIL8_R human interleukin 8 (reverse) AAATTTGGGGTGGAAAGGTT
hIL1B_F human interleukin 1β (forward) GCATCCAGCTACGAATCTCC
hIL1B_R human interleukin 1β (reverse) GCATCTTCCTCAGCTTGTCC
hDNMT1_F human DNA methyltransferase 1 (forward) AGGCAGTTCAACACCCTCAT
hDNMT1_R human DNA methyltransferase 1 (reverse) TGACGGTTGTGCTGAAGAAG
hTNFa_F human tumor necrosis factor α (forward) CCTGTGAGGAGGACGAACAT
hTNFa_R human tumor necrosis factor α (reverse) GGTTGAGGGTGTCTGAAGGA
doi:10.1371/journal.pone.0131699.t001
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Immunocytochemical analysis
From the HT-29 cell suspension 2.5 ml was used for immunocytochemical (ICC) analyses.
HT-29 cells were cyto-centrifuged onto a coverslip and fixed in methanol at -20°C for 10 min,
and then incubated in TBS containing 1% bovine serum albumin, 10% normal goat serum, 0.3
M glycine and 0.1% Tween 20, for 1h to permeabilize the cells and block non-specific protein-
protein interactions.
2x105 HDFα fibroblasts were seeded to a Lab-Tek 8-well chamber slides in 500 μl media
(Thermo Scientific, Rochester, NY) and cultured until 80–90% confluence. After DNA treat-
ment the cells were fixed in ice cold methanol at -20°C for 10 min, and then incubated in PBS
containing 1% bovine serum albumin, /10% normal goat serum, /0.3 M glycine and in 0.1%
Tween 20, TBS-Tween for 1h to permeabilize the cells and block non-specific protein—protein
interactions.
For immunostaining, cells were treated with mouse anti-human monoclonal anti-TLR9 IgG
(1:300; ab85860, Abcam, Cambridge, MA, USA), and anti-DNMT3a IgG (1:300; ab13888,
Abcam, Cambridge, MA, USA) at 4°C overnight, using HeLa cells as a positive control; anti-
cytokeratin 20 (1:200, clone: PCK-26, Dako, Glostrup, Denmark), E-cadherin (1:2, clone:
ECH6, Histopathology Ltd, Pecs, Hungary) using human colonic mucosa as a positive control;
and rabbit anti-NFκB IgG (1:100, GTX102090, Genetex, San Antonio, Texas, USA) using
HepG2 cells as a positive control.
Sections were incubated for 30 min with peroxidase-labeled polymer-horseradish peroxi-
dase (HRP) conjugated to goat anti-mouse/rabbit immunoglobulins (Envision + System-
HRP-DAB; Dako, Glostrup, Denmark). Staining was completed by incubation with
3,30diaminobenzidine chromogen solution (chromogen solution is part of Envision kit). The
sections were counterstained with hematoxylin.
ICC evaluation
Slides were digitalized using a high resolution Panoramic Scan instrument (3DHistech Ltd.,
Hungary) and analyzed with the Panoramic Viewer Histoquant Module software (3DHistech
Ltd., Hungary). 1000 cells/slide were evaluated. In the case of E-cadherin, CK20, cytoplasmic
immunoreactions were scored as negative (-), weak (+), moderate (++) and strong (+++).
NFκB, DNMT3a nuclear/cytoplasmic expressions were scored as negative (-), weak (+), mod-
erate (++) and strong (+++) immunoreactions. The density of negative (-), weak (+), moderate
(++) and strong positive (+++) pixels in immunoreactive cells was evaluated.
Results
Effect of normal and malignant epithelial DNA to HT-29 cells
First, we treated the HT-29 cells with DNA isolated from normal or tumor tissue. Both treat-
ments induced mRNA overexpression of metallothionein genes (i.e. MT1H, MT1G, MT1X,
MT1P2 and MT2A) (metallothionein 1H, -1G, -1X, -1P2, -2A) (Fig 1A and 1B). Tumor tissue
derived DNA treatment resulted in significant overexpression of n = 118 genes (at the mRNA
level). Among these genes, we observed metastasis associated genes e.g., tumor biomarker
CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), metabolic genes e.g.
INSIG1 (insulin induced gene 1) LIPG (endothelial lipase) and messenger molecule genes
DAPP1(dual adaptor of phosphotyrosine and 3-phosphoinositides), CREB3L2 (cAMP respon-
sive element binding protein 3-like 2) (Table 2)
A complete list of regulated genes is available at (http://www.ncbi.nlm.nih.gov/geo) with
accession number GSE67557.
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Analysis of 12 elements of TLR9 pathway in HT-29 cells by qRT—PCR
In HT-29 cells either tumor and healthy colon tissue derived DNA significantly affected the
expression of IL-1β gene related to PBS treated controls. The overexpression of this gene was
higher after tumor tissue derived DNA treatment (log Fc 2.33; p0.05), than in samples treated
with normal DNA (log Fc 1.59; p0.05) related to untreated controls (Fig 2A and 2B).
Cell viability assays
The results of trypan blue exclusion test reflected that tumor cell free DNA treatment signifi-
cantly increased living cell number in the relation to control group (av. 54.22±3.03 vs. 42.00
±3.78; p0.05). We also detected significantly decreased number of living cells in normal DNA
treated group related to control group (av. 28.67±3.08 vs. 42.00±3.78; p0.05); (Fig 3A and 3B).
The PI cell cycle analysis showed significantly higher living cell population (G1+S+G2+M
phase) in tumor DNA treated group vs. control group (av. 39.11±0.57 vs. 32.00±2.50; p0.05).
Fig 1. Heat map representing RNA expression changes in control HT-29 cells and HT-29 cells treated with DNA isolated from healthy(A) and tumorous(B)
colonic epithelium.
doi:10.1371/journal.pone.0131699.g001
Table 2. Significant gene expression changes after tumor tissue-originated DNA treatment in HT-29
cells.
Role in tumorigenesis Gene symbols References
metastasis associated genes MACC1, MALAT1, TACSTD2 [31],[32],[29]
tumor biomarker CEACAM5 [30]
metabolic genes INSIG1, LIPG [31, 32]
messenger molecule genes DAPP, CREB3L2 [33]
doi:10.1371/journal.pone.0131699.t002
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Normal DNA treatment did not affected the cell cycle of counted cells, but we observed a lower
cell count in normal DNA treated samples (Fig 3C).
Effect of normal and malignant epithelial DNA on fibroblast cells
Treatment of HDFα fibroblasts with normal DNA resulted in overexpression of many genes in
the TLR9 MYD88 pathway, cytokines, chemokines, growth factors, apoptosis related genes,
and prostaglandins. In total, DNA from normal colon tissue resulted in a significant expression
change for n = 613 genes (Fig 4A). In contrast, treatment with tumor tissue-derived DNA
affected the expression of only n = 12 genes (Fig 4B).
Important gene expression changes induced by healthy tissue originated DNA treatment in
HDFα cells are summarized in Table 3. The cell free DNA induced the upregulation of chemo-
kine ligands as chemotactic factors, prostaglandins and receptors for prostaglandines in addi-
tion to the DNA sensing pathways.
Following tumor DNA treatment of HDFα fibroblasts, we observed no overexpression of
the elements of TLR9 pathway, chemokines, growth factors, apoptosis related genes, prosta-
glandines and receptors for prostaglandines.
A complete list of regulated genes is available at (http://www.ncbi.nlm.nih.gov/geo) with
accession number GSE67557.
Fig 2. Expression changes of TLR9 MYD88 dependent pathway genes on Affymetrix U 133 2.0 microarray in control, normal and tumorous DNA treated
samples(A) Figure and q RT-PCR analysis of TLR9MYD88 dependent pathway of HT-29 cells(B).
doi:10.1371/journal.pone.0131699.g002
Fig 3. Number of living(A) and dead(B) HT-29 cells determined by Trypan blue exclusion test; PI cell-cycle analysis of HT-29 colon cancer cells(C).
doi:10.1371/journal.pone.0131699.g003
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Analysis of 12 elements of TLR9 pathway in fibroblasts by qRT-PCR
Five genes of canonical TLR9 pathway (IRAK2, MYD88, NFKB, IL-8, IL-1β) showed signifi-
cant overexpression after the treatment with normal tissue derived cell free DNA related to
control cells. Tumor tissue derived DNA treatment did not affected the genes of TLR9 MYD88
pathway. (Log Fc1; p0.05); (Fig 5A and 5B).
ICC analysis of epithelial differentiation, adhesion and methylation
markers
Here we selected three epithelial markers i.e. CK20. E-cadherin, DNMT3a based on our previ-
ous results. [28] PBS treated HT-29 cells showed weak membrane CK20 (Fig 6A), E-cadherin
(Fig 6D) and weak/moderate cytoplasmic DNMT3a (Fig 6G) protein expression. Tumor DNA
treatment induced increase in expression of CK20 strong positive (+++) pixels, (Fig 6C) E-
cadherin weak (+) and moderate (++) positive pixels (Fig 6F) and DNMT3a weak (+) positive
Fig 4. Heat map representing RNA expression changes in control HDFα cells and HDF-α cells treated with DNA isolated from healthy (A) and tumorous (B)
colonic epithelium.
doi:10.1371/journal.pone.0131699.g004
Table 3. Significant gene expression changes after normal colon tissue-originated DNA treatment in
HDFα fibroblasts.
Role in tumorigensis Gene symbols References
TLR9 MYD88 pathway MYD88, IRAK2, TRAF6, NFκB, IL6, IL8, IRF7, IFN-β [21]
STING/cGAS pathway ADAR, NFκB, CASP1, CXCL10, IRF7, IFN-β, IL-6 [34]
chemokines CCRL1, CCL8, CXCL3, CXCL5, CXCL10, CXCL11
fibroblast growth factor FGF2
apoptosis related genes CASP7,CFLAR, BCL2
prostaglandines PTGS2, PTGFR
doi:10.1371/journal.pone.0131699.t003
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Fig 5. Expression changes of TLR9 MYD88 dependent pathway genes on Affymetrix U 133 2.0 microarray in control, normal and tumorous DNA treated
samples(A) and q RT-PCR analysis of TLR9 MYD88 dependent pathway on HDF alpha cells(B).
doi:10.1371/journal.pone.0131699.g005
Fig 6. CK20 expression in HT-29 colon cancer cells after the treatment by sterile PBS(A), by DNA from normal colon epithelium (B), by DNA from tumorous
colon epithelium (C) E-cadherin expression after the treatment by sterile PBS(D), by DNA from normal colon epithelium(E), by DNA from tumorous colon
epithelium(F) DNMT3a expression after the treatment by sterile PBS(G), by DNA from normal colon epithelium(h), by DNA from tumorous colon epithelium(I).
doi:10.1371/journal.pone.0131699.g006
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pixels (Fig 6I). (p0.05). Tumor DNA promoted CK20 and E-cadherin expression in the non-
differentiated, HT—29 colon adenocarcinoma cells both on mRNA and protein level (Table 4,
Fig 6C and 6F) (p0.05). DNMT3a protein overexpression correlated with the previous results
[28].
ICC analysis of transcription factors and methylation markers in
fibroblasts
The NF-κB (p65 subunit) reflected weak cytoplasmic / nucleolic expression in PBS treated con-
trol fibroblasts (Fig 7D). By the effect of normal tissue DNA (Fig 7E), but not tumor tissue orig-
inated DNA, (Fig 7F) the fibroblasts reflected increase in expression of NFκB weak positive
pixels (+).
The cytoplasmic DNMT3a expression was on a weak (+), moderate (++) level in normal
fibroblasts (Fig 7A). The ratio of weak (+) positive pixels was slightly increased after normal
and tumor DNA treatment (Fig 7B and 7C).
Our immunocytochemical results on HT-29 cells and HDFα fibroblasts are summarized in
the Fig 8A, 8B, 8C, 8D and 8E.
Table 4. Table representing RNA expression change of CDH1 and KRT 20 after normal and tumor tissue derived DNA treatment.
Probe Set ID Gene
Symbol
t-test (Control vs Normal
DNA treatment)
t-test (Control vs Tumor
DNA treatment)
Log FC (Normal DNA
treatment vs Control)
Log FC (Tumor DNA
treatment vs Control)
201131_s_at CDH1 0,030924 0,004002 0,25845 0,735174
213953_at KRT20 0,057182 0,007309 0,177712 0,741828
doi:10.1371/journal.pone.0131699.t004
Fig 7. DNMT3a expression in HDF alpha fibroblasts after the treatment by sterile PBS(A), by DNA from normal colon epithelium(B), by DNA from tumorous
colon epithelium(C), NFκB expression after the treatment by sterile PBS(D), by DNA from normal colon epithelium(E), by DNA from tumorous colon
epithelium(F).
doi:10.1371/journal.pone.0131699.g007
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Discussion
The main aim of our work was to examine changes in gene expression following administration
of cell free DNA isolated from healthy and tumorous colonic tissue on HT-29 epithelial cells
and fibroblasts. We are not aware of any studies that have examined expression changes in the
two different cell types cooperating during tumorigenesis or the effect of cell free DNA from
different origins. According to recent published studies, bacterial DNA activates DNA sensing
receptors, possibly due to the frequency of unmethylated CpG sequences in bacterial genome,
which is 20 fold higher than in vertebrates’ genome.[35] From further studies it was clear that
DNA from pathogenic bacteria upregulate TLR9 expression [15], In the present study we have
examined the gene expression changes induced by DNA of tumor origin in cancer cells, by
whole genome array. This approach is similar to that reported by Lee et. al. (2014) who demon-
strated the uptake, incorporation and effect of this tumor tissue originated DNA on cell prolif-
eration.[13]
Our gene expression results are confirmed align with observations in recent publications
that demonstrated that intact tumor DNA binds as a ligand to TLR9 but does not result in
downstream activation of TLR9 pathway [36]. In our study, our whole genome array results
provided evidence that tumorous DNA acts as a pro-metastatic factor independently from the
TLR9 and STING pathways by inducing overexpression of metastasis-associated genes
(MACC1, MALAT1,TACSTD2), the tumor marker (CEA), metabolic genes (INSIG1, LIPG)
and messenger molecule genes (DAPP, CREB3L2). MACC1 is an important pro-metastatic
factor that showed significant overexpression following treatment with tumor DNA. This gene
is closely associated with the alterations of expressions of cell cycle- and invasion-related pro-
teins.[37] Our results reflecting overexpression of other important pro—metastatic genes
(MACC1, MALAT1, TACSTD2) are confirmed by previous data reflecting the major role of
these genes in metastasis and their association with poor prognosis in various human epithelial
cancers.[29, 37, 38]
Tumor tissue derived DNA treatment affected INSIG 1 and LIPG expression. These two key
elements of endothelial lipid metabolism are also known to be associated with cancer progres-
sion. [31, 32]Increased LIPG expression was reported as a possible urinary cancer biomarker.
Fig 8. ICC evaluation of CK20(A), E-cadherin(B) and DNMT3a(C) on HT-29 colon cancer cells and NFκB(D) and DNMT3a(E) in HDF alpha fibroblasts.
doi:10.1371/journal.pone.0131699.g008
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[32] Studies described increased expression of secondary messenger molecules (DAPP,
CREB3L2) in colon cancer with the growth and invasion of colon cancer cells via PI3K/AKT
pathway activation.[33]
We observed that treatment with tumor DNA also results in overexpression of cytokeratin
20, and E-cadherin which was validated both at the RNA (Table 4) and the protein level
(Fig 6C and 6F). E-cadherin as a very important factor regulating cell—cell interaction also
showed higher expression in HT-29 cells treated with tumor DNA. E-cadherin overexpression
leads to the suppression of β-catenin-Tcf/Lef-dependent transcription and likely inhibits cell
apoptosis. [39]
DNA methylation changes mediated by DNMT3a are characteristic of colon cancers. Re-
expression of factors targeting DNMT3a expression significantly decreased tumor growth.
DNMT3a overexpression after treatment with tumor DNA infers a potential connection
between the methylation status of tumor tissue derived DNA and the mechanism of action of
tumor tissue derived DNA sequences acting through DNA sensing receptors. Former studies
highlight a crucial role of this enzyme in colorectal cancer formation.[40]
Colon cancer tissue is not isolated, but with its cellular milieu through chemokines, cyto-
kines, growth and apoptosis signals is communicating with other tissues. Studies have exam-
ined the role of the normal and cancer associated fibroblasts (CAFs) in colorectal cancer and
showed that CAFs co-cultured with epithelial cells increases the tumor growth [41], but they
do not determine the role of normal fibroblasts separately in tumorigenesis. Our aim was to
determine the reaction of normal fibroblasts around the epithelial crypts to the released DNA
and to screen the pathways included in that process.
In normal fibroblast treatment with DNA from normal tissue caused activation of the TLR9
canonic pathway, as qRT-PCR revealed overexpression of many genes involved in TLR9
MYD88 dependent pathway (MYD88, IRAK2, NFκB, IL-8, IL-1β).
From whole genome microarray analysis results we can conclude that healthy DNA in fibro-
blast is not only recognized by TLR9 MYD 88 dependent pathway, but we found that the ele-
ments of STING-dependent cytosolic pathway also showed significant overexpression, which
initiates IFN production. Using the KEGG pathway map (http://www.genome.jp/kegg-bin/
show_pathway?hsa04623+340061) 4 genes (ADAR, IRF7, CXCL10, CASP1) from the STING
pathway showed significant overexpression after the treatment with healthy DNA in HDF-α
fibroblasts. This activated cGAS/STING-dependent DNA sensing pathway induced overex-
pression of interferon regulatory factors IRF1, IRF2, IRF7, IRF9. and induced increased expres-
sion of interferon receptor genes (IFNAR2, IFNGR2). (log FC1, p0.05) The overexpression
of CASP1 and NLRC 5 suggest NLRC5-dependent activation of the inflammasome. Davis et.
al. published that NLRC5 cooperates with NLRP3and RNA interference-mediated knockdown
of NLRC5 nearly eliminated caspase 1 activity. [42]
NFκB as a transcription regulatory factor showed significant overexpression in the fibro-
blasts treated by normal DNA. (Fig 7E) It shows that cell free DNA induced NFκB transloca-
tion regulating the release of pro-inflammatory cytokines and growth factors.
Whole genome microarray analysis showed a strikingly different number of genes regulat-
ing healthy and tumor tissue derived DNA administration (613 and 12 genes, respectively).
While healthy DNA activated DNA sensing systems and upregulated many genes for cyto-
kines, chemokines, growth factors, apoptosis related genes, prostaglandins, tumor DNA
affected only few genes, that do not involve in this regulating processes. We think that normal
fibroblasts do not react to tumor DNA and a long-term cancer-fibroblast interaction could ini-
tiate a transformation of normal fibroblasts to carcinoma-associated fibroblasts supporting
“metastatic” phenotype.
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Our study points the possible metastasis promoting effect of the tumor originated DNA via
TLR9 independent pathway due to the overexpression of metastasis associated genes, meta-
bolic genes and signaling pathways driving promoting cancer cell invasion. Differences in the
physical properties of DNA isolated from tumor versus normal tissue suggests different mecha-
nism of action in non-malignant and cancer cells through the activation of different pathways.
Recently published works highlight that during the oncogenic transformation, in addition to
changes in methylation status, other structural changes are observed, including changes in the
expression of oncogenes and tumor suppressor genes, aberrant microsatellites, and rearranged
chromosomal DNA incorporation to host cells genome.[13] Based on the tumor promoting
effect the cf—DNA it´s degradation could be a possible therapeutical target achieved by
DNAse treatment.[5]
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